Sahir Raoof closes $27.5M debut fund Proximal Ventures for AI drug-development startups
Former SignalFire investor Sahir Raoof has raised $27.5 million for his first solo venture fund, Proximal Ventures, which targets startups applying AI to pharmaceutical development tools and services. The firm writes pre-seed and seed checks of $500,000 to $1.5 million and has already backed six companies, including ChronicleBio, co-founded by former OpenAI executive Fidji Simo.
GoKawiil's interpretation of the reporting above, not reported fact.
Raoof argues that pharma has long relied on outsourced services rather than software, and he believes AI could let startups replicate those services more cheaply and quickly, potentially capturing a large share of industry spending. The fund's success in a difficult environment for first-time managers suggests investors see enough promise in AI-driven pharma services to back an unproven solo GP.
- Proximal Ventures raised $27.5M as Sahir Raoof's debut solo fund
- The firm targets pre-seed/seed startups applying AI to drug development services with $500K-$1.5M checks
- Portfolio already includes six startups, including ChronicleBio co-founded by Fidji Simo
Source: techcrunch.com — Marina Temkin, 2026-11-10
Published there as: “Proximal Ventures raises debut fund to back startups bringing AI to drug development”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.